The role of chemokine receptors in HIV infection

Sexually Transmitted Infections

Volumn 75, Issue 3, 1999, Pages 148-151

  Rowland Jones, Sarah ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENE BIS(METHYLENE)] BIS 1,4,8,11 TETRA AZACYCLOTETRADECANE; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; DENDRITIC CELL; EDITORIAL; GENE MUTATION; GENETIC POLYMORPHISM; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032966430     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.75.3.148     Document Type: Editorial

References (40)

1. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-62.
2. Horuk R. Chemokine receptors and HIV-1: the fusion of two major research fields. Immunol Today 1999;20:89-91.
3. Cocchi F, DeVico AL, Garzino DA, et al. Identification of RANTES, MIP-I alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-15.
4. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of TH1 lymphocytes. Nature 1998;391:344 5.
5. Patterson BK, Landay A, Andersson J, et al. Repertoire of Chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998;153:481-90.
6. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-25.
7. Austyn JM, Dendritic cells. Curr Opin Hematol 1998;5:3-15.
8. Rowland-Jones SL. HIV: the deadly passenger in dendritic cells. Curr Biol 1999;9:R248-50.
9. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals in HIV-1 infection. Cell 1996;88:7-20.
10. Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32 base-pair deletion. Nat Genet 1997;16:100-3.
11. Connor RI, Mohri H, Cao Y, et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T lymphocyte decline and clinical progression in HIV-1 infected individuals. J Virol 1993;67:1772-7.
12. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185: 621-8.
13. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci 1997;94:1925-30.
14. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-74.
15. Penn ML, Grivel JC, Schramm B, et al. CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999;96:663-8.
16. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9.
17. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract [see comments]. Nature 1998;393: 591-4.
18. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382:635-8.
19. Pleskoff O, Treboute C, Brelot A, et al. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 1997;276:1874-8.
20. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997;277:1656-9.
21. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62.
22. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-65.
23. Anzala AO, Ball TB, Rostron T, et al for the Nairobi HIV study group. The 64I allele of the CCR2 chemokine receptor is strongly associated with delayed disease progression in a cohort of African prostitutes. Lancet 1998;351:1632-3.
24. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-93.
25. Lee B, Doranz BJ, Rana S, et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998;72:7450-8.
26. Kostrikis L, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998;4: 350-3.
27. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352:866-70.
28. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-11.
29. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998;279:389-93.
30. Kinter A, Catanzaro A, Monaco J, et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc Natl Acad Sci USA 1998;95:11880-5.
31. Gordon CJ, Mucsing MA, Proudfoot AE, et al. Enhancement of human immunodeficiency virus type 1 infection by the CC- chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999;73:684-94.
32. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9.
33. Arenzana-Seisdedos F, Virelizier JL, Rousset D, et al. HIV blocked by chemokine antagonist. Nature 1996;383:400.
34. Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997;186;1373-81.
35. Baggiolini M, Moser B. Blocking chemokine receptors. J Exp Med 1997;186:1189-91.
36. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-93.
37. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-8.
38. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-400.
39. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nat Med 1998;4:72-7.
40. Arakaki R, Tamamura H, Premanathan M, et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-23.